Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hormone shot before embryo transfer may boost pregnancy chances in severe endometriosis

NCT ID NCT07696351

Disease control Sponsor: Li-jun Ding Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether giving two injections of a long-acting hormone (GnRH-a) before standard hormone therapy can improve pregnancy rates in women with deep infiltrating endometriosis undergoing their first frozen embryo transfer. The hormone pretreatment aims to suppress endometriosis lesions and reduce inflammation, potentially making the womb lining more receptive. Participants are randomly assigned to receive either the hormone pretreatment plus standard therapy or standard therapy alone, and the main outcome is the rate of clinical pregnancy detected by ultrasound.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triptorelin (GnRH agonist)
What this could lead to
If successful, this approach could increase the chance of pregnancy after frozen embryo transfer for women with deep infiltrating endometriosis.
What could go wrong
This is a mid-stage trial with 120 participants, so results may not apply to all patients. GnRH agonists can cause side effects like hot flashes and mood changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 39 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients aged 18 to 39 years. 2. Diagnosed with deep infiltrating endometriosis by ultrasound at the study center. 3. Undergoing the first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation. 4. Having at least one good-quality frozen embryo. 5. Willing to participate in this randomized controlled study of GnRH-a pretreatment for deep infiltrating endometriosis and able to personally sign the written informed consent form. Exclusion Criteria: 1. Abnormal chromosomal karyotype. 2. Other uterine diseases or conditions that may affect uterine cavity morphology or pregnancy outcomes, including intrauterine adhesions affecting the uterine cavity, intramural uterine fibroids, moderate to severe adenomyosis, congenital uterine malformation, endometrial tuberculosis, or endometrial thickness less than 8 mm on the transformation day. 3. Recurrent implantation failure. 4. Contraindications to hormone replacement therapy or long-acting GnRH-a treatment. 5. Osteoporosis or depressed mood. 6. Currently participating in another clinical study. 7. Unable to adhere to study visits and follow-up, or planning to receive other treatment during the follow-up period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep infiltrating endometriosis (DIE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep infiltrating endometriosis (DIE) Infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Affiliated Drum Tower Hospital of Nanjing University Medical School

    RECRUITING

    Nanjing, Jiangsu, 216000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.